Search
ADC Therapeutics SA
ADCTAdd to Watchlist
1.070USD
-0.040-3.60%
Close 09-11 16:00（ET）
135.08MMarket Cap
LossP/E TTM
After-hours 19:00 (ET)1.070USD+0.005+0.47%
After-hours 19:00 (ET)ADC Therapeutics SA (ADCT) Stock Price Target & Forecast
Analyst Rating
Based on 6 analysts giving stock ratings to ADC Therapeutics SA in the past month.
Buy
2 Strong Buy
1 Buy
2 Hold
0 Sell
1 Strong Sell
Target Price
2.625USD+115.16%
ADCT Analyst Recommendation Trends
In the current month, ADCT has received 1 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ADCT average Analyst price target in the last month is 2.625.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
2
2
3
3
3
3
3
3
1
1
3
3
3
3
3
3
2
2
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
6
6
6
6
6
6
6
ADCT Analyst Rating for Peer Comparison
Updated: Sep 11, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Revolution Medicines Inc
RVMD
8
12
1
0
0
21
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, ADCT EPS is projected to reach -0.213 in FY2026Q3, following reported EPS of -0.107 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.27
-0.21
-0.21
-0.21
-0.20
Actual
-0.04
-0.21
-0.11
--
--
Surprise
+84.14%
+0.52%
+49.59%
--
--
FAQs
What is ADC Therapeutics SA's expected revenue for the next quarter?
ADC Therapeutics SA's expected revenue is 18.44M.
What is ADC Therapeutics SA's price target?
Analysts forecast that ADC Therapeutics SA's price target is USD 2.62, with the highest forecast at USD 5.00 and the lowest forecast at USD 0.50.
How have ADC Therapeutics SAADCT's recent earnings per share performed?
The market expectation was USD -0.11, while ADC Therapeutics SAADCT's earnings per share (EPS) for the previous quarter was USD -0.21. EPS for the next quarter is expected at USD -0.21.
What is the analyst rating for ADC Therapeutics SA?
Based on the ratings of ADC Therapeutics SA's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.